| 000 | 01609 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250516184524.0 | ||
| 264 | 0 | _c20140408 | |
| 008 | 201404s 0 0 eng d | ||
| 022 | _a2168-6157 | ||
| 024 | 7 |
_a10.1001/jamaneurol.2013.4915 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDiekman, Eugene F | |
| 245 | 0 | 0 |
_aSurvival and psychomotor development with early betaine treatment in patients with severe methylenetetrahydrofolate reductase deficiency. _h[electronic resource] |
| 260 |
_bJAMA neurology _cFeb 2014 |
||
| 300 |
_a188-94 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article; Meta-Analysis; Review | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aBetaine _xadministration & dosage |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHomocystinuria _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 | _aInfant, Newborn |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethylenetetrahydrofolate Reductase (NADPH2) _xdeficiency |
| 650 | 0 | 4 |
_aMuscle Spasticity _xdrug therapy |
| 650 | 0 | 4 |
_aPsychomotor Disorders _xenzymology |
| 650 | 0 | 4 |
_aPsychotic Disorders _xdrug therapy |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 |
_aSurvival Rate _xtrends |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _ade Koning, Tom J | |
| 700 | 1 | _aVerhoeven-Duif, Nanda M | |
| 700 | 1 | _aRovers, Maroeska M | |
| 700 | 1 | _avan Hasselt, Peter M | |
| 773 | 0 |
_tJAMA neurology _gvol. 71 _gno. 2 _gp. 188-94 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1001/jamaneurol.2013.4915 _zAvailable from publisher's website |
| 999 |
_c23352895 _d23352895 |
||